TruScreen censured after falling short of NZ resident director requirements

TruScreen censured after falling short of NZ resident director requirements
Tina Morrison
By Tina Morrison Feb. 13 (BusinessDesk) - TruScreen, the cervical cancer test developer which is listed on the NZX Alternative Market, has been publicly censured by the New Zealand Markets Disciplinary Tribunal for having just one New Zealand resident director for 18 business days, falling short of the requirement for at least two, after former director Tim Preston withdrew his nomination on the eve of the company's annual meeting in September. The stock market's disciplinary tribunal said TruScreen had only one director who was ordinaril...